MERRIMACK PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.13 USD | 0.00% |
|
+0.07% | +12.83% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 192M |
|---|---|---|---|---|---|
| Net income 2022 | -1M | Net income 2023 | -1M | EV / Sales 2022 | - |
| Net cash position 2022 | 19.44M | Net cash position 2023 | 18.88M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-100
x | P/E ratio 2023 |
-162
x | Employees | 27 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 97.07% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +0.07% | ||
| Current month | +2.65% | ||
| 1 month | +3.07% | ||
| 3 months | +2.93% | ||
| 6 months | +18.02% | ||
| Current year | +12.83% |
1 week
15.10
15.17
1 month
14.7015.17
Current year
12.9415.89
1 year
11.5315.89
3 years
3.0015.89
5 years
1.4915.89
10 years
1.49138.40
| Managers | Title | Age | Since |
|---|---|---|---|
Ulrik Nielsen
FOU | Founder | 52 | 92-12-31 |
Gary Crocker
CEO | Chief Executive Officer | 72 | 03-12-31 |
| Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gary Crocker
CEO | Chief Executive Officer | 72 | 03-12-31 |
| Director/Board Member | 45 | 19-09-18 | |
Ulrik Nielsen
FOU | Founder | 52 | 92-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.50% | 4 M€ | -5.15% | - | |
| 0.00% | 34 M€ | +3.87% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 15.13 | 0.00% | 1,255,765 |
| 24-05-16 | 15.13 | 0.00% | 869,211 |
| 24-05-15 | 15.13 | +0.07% | 372,606 |
| 24-05-14 | 15.12 | +0.13% | 1,934,525 |
| 24-05-13 | 15.1 | -0.13% | 513,850 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. It is entitled to receive payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. These payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of Onivyde for certain additional clinical indications. ONIVYDE is approved by FDA to market as a first-line treatment of metastatic adenocarcinoma on the pancreas. It is also entitled to receive payments related to its sale of anti-HER3 programs to Elevation Oncology, Inc. The Companyâs wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| +12.83% | 224M | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B | |
| -6.26% | 11.42B |
- Stock Market
- Equities
- MACK Stock
